See analyst estimates and all valuation multiples for Regenerative Medicine
Company | EV | EV/LTM Revenue | EV/LTM EBITDA |
---|---|---|---|
$118B | 10.3x | 36.4x | |
$10.8B | 3.6x | 14.0x | |
$3.9B | 12.3x | 29.8x | |
$3.7B | 10.6x | 28.1x | |
$3.6B | 90.7x | -7.8x | |
$2.5B | 692.7x | -64.6x | |
$2.2B | 3.8x | 33.9x | |
$2.1B | 7.9x | 32.4x | |
$1.5B | n/a | n/a | |
$1.5B | 67.9x | -50.5x | |
$1.1B | 18.8x | -2.6x | |
$1.1B | 1819.9x | -43.9x | |
$940M | 2.6x | 12.1x | |
$872M | 15.4x | -1.9x | |
$624M | 1.3x | 12.3x | |
$582M | 2.9x | 26.3x | |
$560M | 7.9x | 28.4x | |
$471M | 16.7x | -2.9x | |
$470M | n/a | n/a | |
$431M | 12.1x | 24.5x | |
$378M | 5.4x | -22.4x | |
$347M | 85.4x | n/a | |
$313M | 258.1x | n/a | |
$288M | n/a | n/a | |
$237M | 2456.2x | -1.4x | |
$196M | 24.5x | -8.3x | |
$186M | 0.6x | n/a | |
$178M | 29.1x | -55.7x | |
$170M | n/a | n/a | |
$154M | 5.4x | 11.0x | |
$132M | 1.1x | 17.9x | |
$121M | 2.2x | 39.0x | |
$119M | n/a | n/a | |
$109M | 4.1x | -8.9x | |
$91.6M | n/a | n/a | |
$71.2M | n/a | -5.1x | |
$59.3M | n/a | n/a | |
$51.9M | 192.3x | -0.2x | |
$48.3M | 35.1x | n/a | |
$24.3M | n/a | n/a | |
$23.0M | n/a | n/a | |
$20.7M | 5.2x | n/a | |
$16.8M | 21.8x | -3.5x | |
$9.8M | 1.7x | n/a | |
$9.5M | 4.6x | n/a | |
-$161M | -2.7x | 0.8x |
Valuation multiples as of last 12 months (LTM). Financial data powered by Morningstar, Inc.
See analyst estimates and M&A multiples for Regenerative Medicine